Literature DB >> 19183180

Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors.

C Sunderkötter1, I Herrgott, C Brückner, P Moinzadeh, C Pfeiffer, J Gerss, N Hunzelmann, M Böhm, T Krieg, U Müller-Ladner, E Genth, E Schulze-Lohoff, M Meurer, I Melchers, G Riemekasten.   

Abstract

BACKGROUND: Digital ulcers (DU) are a major complication in the course of systemic sclerosis (SSc). In recent years, efficacious, but expensive therapies (e.g. iloprost, sildenafil, bosentan) have been shown to improve healing or to reduce the recurrence of DU. For optimal management it would be useful to identify the risk factors for DU. Such statistical analyses have been rare because they require a high number of patients.
OBJECTIVES: To identify potential risk factors for DU in patients with SSc.
METHODS: We used the registry of the German Network for Systemic Scleroderma and evaluated the data of 1881 patients included by August 2007. We assessed potential risk factors for DU by comparing patients with (24.1%) and without active DU at time of entry (75.9%).
RESULTS: Multivariate analysis revealed that male sex, presence of pulmonary arterial hypertension (PAH), involvement of the oesophagus, diffuse skin sclerosis (only when PAH was present), anti-Scl70 antibodies, young age at onset of Raynaud's phenomenon (RP), and elevated erythrocyte sedimentation rate (ESR) significantly impacted on the appearance of DU. Certain combinations increased the patients' probability of presenting with DU, with the highest probability (88%) for male patients with early onset of RP, ESR>30 mm h(-1), anti-Scl70 antibodies and PAH. Patients with DU developed RP, skin sclerosis and organ involvement approximately 2-3 years earlier than patients without DU.
CONCLUSIONS: The results reveal possible risk factors for the occurrence of DU in SSc. As DU are prone to local complications, prophylactic vasoactive treatment for patients presenting with these factors may be justified.

Entities:  

Mesh:

Year:  2009        PMID: 19183180     DOI: 10.1111/j.1365-2133.2008.09004.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  30 in total

1.  [Critical limb ischemia in systemic sclerosis].

Authors:  M O Becker; G Riemekasten
Journal:  Z Rheumatol       Date:  2012-06       Impact factor: 1.372

Review 2.  [Therapeutic management in early disease stages of systemic sclerosis : early diagnosis - early symptoms - early problems].

Authors:  M Frerix; F M P Meier; W Hermann; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2013-12       Impact factor: 1.372

3.  Late-age onset systemic sclerosis.

Authors:  Rebecca L Manno; Fredrick M Wigley; Allan C Gelber; Laura K Hummers
Journal:  J Rheumatol       Date:  2011-06-17       Impact factor: 4.666

4.  [Systemic scleroderma].

Authors:  N Hunzelmann
Journal:  Hautarzt       Date:  2013-04       Impact factor: 0.751

5.  Enrichment of Scleroderma Vascular Disease-Associated Autoantigens in Endothelial Lineage Cells.

Authors:  Zsuzsanna H McMahan; Tricia R Cottrell; Fredrick M Wigley; Brendan Antiochos; Elias T Zambidis; Tea Soon Park; Marc K Halushka; Laura Gutierrez-Alamillo; Raffaello Cimbro; Antony Rosen; Livia Casciola-Rosen
Journal:  Arthritis Rheumatol       Date:  2016-10       Impact factor: 10.995

6.  [Digital ulcers in systemic scleroderma].

Authors:  D Belz; N Hunzelmann; P Moinzadeh
Journal:  Hautarzt       Date:  2014-11       Impact factor: 0.751

7.  Vascular complications in systemic sclerosis: a prospective cohort study.

Authors:  Christopher A Mecoli; Ami A Shah; Francesco Boin; Fredrick M Wigley; Laura K Hummers
Journal:  Clin Rheumatol       Date:  2018-05-26       Impact factor: 2.980

8.  [Digital ulcers in systemic sclerosis : A retrospective heath service study analysing treatment with bosentan and other vasoactive therapies].

Authors:  G Riemekasten; S Beissert; J H W Distler; A Kreuter; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2017-04       Impact factor: 1.372

Review 9.  Clinical and molecular genetics of the phosphodiesterases (PDEs).

Authors:  Monalisa F Azevedo; Fabio R Faucz; Eirini Bimpaki; Anelia Horvath; Isaac Levy; Rodrigo B de Alexandre; Faiyaz Ahmad; Vincent Manganiello; Constantine A Stratakis
Journal:  Endocr Rev       Date:  2013-12-05       Impact factor: 19.871

10.  Registry evaluation of digital ulcers in systemic sclerosis.

Authors:  Felice Galluccio; Marco Matucci-Cerinic
Journal:  Int J Rheumatol       Date:  2010-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.